A new vaccine using the same mRNA technology as the Pfizer jab against COVID-19 could be a breakthrough in the fight against pancreatic cancer.
In a promising early study conducted by German company BioNTech — which partnered with Pfizer to develop the lifesaving COVID shot — half of the patients remained cancer-free 18 months after having their tumors removed and receiving the jabs.